Cognition Therapeutics (CGTX) Other Accumulated Expenses (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Other Accumulated Expenses of $194000.0 for Q1 2026, up 20.5% year-over-year from $161000.0 in Q1 2025, and down 36.81% quarter-over-quarter from $307000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Other Accumulated Expenses for 7 consecutive years, with $194000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 20.5% year-over-year to $194000.0; the TTM figure through Mar 2026 stood at $194000.0 (up 20.5% YoY), while the FY2025 annual figure was $307000.0, up 10.04% from the prior year.
- Other Accumulated Expenses fell to $194000.0 in Q1 2026 per CGTX's latest filing, from $307000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $634000.0 in Q4 2022 and bottomed at $2000.0 in Q1 2022.
- Historically, Other Accumulated Expenses has averaged $253000.0 across 5 years, with a median of $217000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 96.28% — and 2023, when it surged 21250.0%.
- Cognition Therapeutics' Other Accumulated Expenses stood at $634000.0 in 2022, then retreated by 14.2% to $544000.0 in 2023, then plunged by 48.71% to $279000.0 in 2024, then grew by 10.04% to $307000.0 in 2025, then plunged by 36.81% to $194000.0 in 2026.
- Business Quant data shows CGTX's Other Accumulated Expenses at $194000.0 in Q1 2026, $307000.0 in Q4 2025, and $41000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 194,000.00 |
| Dec 31, 2025 | 307,000.00 |
| Jun 30, 2025 | 41,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 279,000.00 |
| Jun 30, 2024 | 185,000.00 |
| Mar 31, 2024 | 366,000.00 |
| Dec 31, 2023 | 544,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 217,000.00 |
| Mar 31, 2023 | 427,000.00 |
| Dec 31, 2022 | 634,000.00 |
| Sep 30, 2022 | 34,000.00 |
| Jun 30, 2022 | 402,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 1.19 Mn |
| Sep 30, 2021 | 913,000.00 |
| Dec 31, 2020 | 5,000.00 |